Primmune Therapeutics Raises $7 Million Seed Financing to Develop Novel Oral TLR7 Immunotherapies for Cancer and Acute Viral Diseases

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/2wsl6AT
via IFTTT